Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has scheduled its first quarter 2025 financial results announcement for May 6, 2025 after market close.
The company will host a conference call and webcast at 4:30 p.m. ET on the same day. Investors can access the live webcast and presentation materials through the 'Events' section of Arcutis' website, with an archived replay available afterward on the company's investor website.
Arcutis Biotherapeutics (Nasdaq: ARQT), un'azienda biofarmaceutica in fase commerciale specializzata in innovazioni nell'immuno-dermatologia, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 6 maggio 2025 dopo la chiusura dei mercati.
La società terrà una conference call e una webcast alle 16:30 ET dello stesso giorno. Gli investitori potranno accedere alla diretta streaming e ai materiali della presentazione nella sezione 'Eventi' del sito web di Arcutis, con una replica archiviata disponibile successivamente sul sito dedicato agli investitori.
Arcutis Biotherapeutics (Nasdaq: ARQT), una empresa biofarmacéutica en etapa comercial especializada en innovaciones en inmunodermatología, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 6 de mayo de 2025 después del cierre del mercado.
La compañía realizará una conferencia telefónica y una transmisión en vivo a las 4:30 p.m. ET del mismo día. Los inversores podrán acceder a la transmisión en vivo y a los materiales de presentación a través de la sección 'Eventos' en el sitio web de Arcutis, con una repetición archivada disponible posteriormente en la página para inversores de la empresa.
Arcutis Biotherapeutics (나스닥: ARQT)는 면역 피부학 혁신을 전문으로 하는 상업 단계의 바이오제약 회사로, 2025년 5월 6일 장 마감 후 2025년 1분기 재무 실적 발표를 예정하고 있습니다.
회사는 같은 날 오후 4시 30분(동부 표준시)에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 투자자들은 Arcutis 웹사이트의 '이벤트' 섹션을 통해 라이브 웹캐스트와 발표 자료에 접속할 수 있으며, 이후 회사 투자자 웹사이트에서 녹화된 재방송을 시청할 수 있습니다.
Arcutis Biotherapeutics (Nasdaq : ARQT), une société biopharmaceutique en phase commerciale spécialisée dans les innovations en immuno-dermatologie, a prévu l'annonce de ses résultats financiers du premier trimestre 2025 pour le 6 mai 2025 après la clôture des marchés.
La société organisera une conférence téléphonique et une webdiffusion à 16h30 ET le même jour. Les investisseurs pourront accéder à la diffusion en direct et aux documents de présentation via la section « Événements » du site d'Arcutis, avec une rediffusion archivée disponible par la suite sur le site dédié aux investisseurs.
Arcutis Biotherapeutics (Nasdaq: ARQT), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf Innovationen in der Immun-Dermatologie spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 6. Mai 2025 nach Börsenschluss geplant.
Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten. Anleger können den Live-Webcast und die Präsentationsunterlagen über den Bereich 'Events' auf der Website von Arcutis abrufen; eine archivierte Wiedergabe wird anschließend auf der Investorenseite des Unternehmens verfügbar sein.
- None.
- None.
WESTLAKE VILLAGE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report first quarter 2025 financial results and provide a business update on Tuesday, May 6, 2025 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET.
A live webcast of the call and the presentation materials will be available on the “Events” section of The Company’s website. An archived replay of the webcast will be available on the Arcutis investor website following the conference call.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Latha Vairavan, Vice President, Finance and Corporate Controller
ir@arcutis.com
FAQ
When will Arcutis (ARQT) release Q1 2025 earnings?
How can investors access Arcutis (ARQT) Q1 2025 earnings call?
Will Arcutis (ARQT) Q1 2025 earnings call materials be available after the event?
What time is Arcutis (ARQT) Q1 2025 earnings call?
